SCHEMBL7077905

SCHEMBL7077905

Cc1ccc(C(=O)NCCN2CCOCC2)c(Nc2ccc3cn[nH]c3c2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.67
PDGFRA P16234 2/20 0.67
SMYD2 Q9NRG4 1/20 0.49
KDM5B Q9UGL1 1/20 0.49
LMNA P02545 2/20 0.45
NPC1 O15118 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
USP2 O75604 1/20 0.44
RAD52 P43351 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KMT2A Q03164 1/20 0.44
KDR P35968 1/20 0.43
POLB P06746 1/20 0.43
LRRK2 Q5S007 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7078467 0.91 PDGFRB (0.56) PDGFRBPDGFRASMYD2LMNANPC1
SCHEMBL6769391 0.87 PDGFRB (0.66) PDGFRBPDGFRASMYD2KDM5BMAOB
SCHEMBL7079355 0.85 PDGFRB (0.51) PDGFRBPDGFRALMNANPC1KDM4E
SCHEMBL7081409 0.83 SYK (0.46) PDGFRBPDGFRALMNANPC1KDM4E
SCHEMBL7078745 0.83 PDGFRB (0.52) PDGFRBPDGFRALMNANPC1KDM4E
SCHEMBL7083122 0.81 RPS6KB1 (0.49) PDGFRBPDGFRALMNANPC1KDM4E
SCHEMBL24625750 0.80 PDGFRB (1.00) PDGFRBPDGFRAPOLB
SCHEMBL29793849 0.80 PDGFRB (1.00) PDGFRBPDGFRAPOLB
SCHEMBL6772093 0.80 PDGFRA (0.57) PDGFRBPDGFRASMYD2KDM5BKDR
SCHEMBL7081591 0.79 SYK (0.43) PDGFRBPDGFRALMNANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US claimed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US claimed
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US disclosed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents TPMT, HAVCR2, NNMT PDGFRB 3908/4885PDGFRA 3543/4885SMYD2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.